Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 10.33
FOLD's Cash to Debt is ranked lower than
58% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. FOLD: 10.33 )
FOLD' s 10-Year Cash to Debt Range
Min: 4.97   Max: N/A
Current: 10.33

F-Score: 2
Z-Score: 3.51
M-Score: -3.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -6302.12
FOLD's Operating margin (%) is ranked lower than
90% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. FOLD: -6302.12 )
FOLD' s 10-Year Operating margin (%) Range
Min: -17680.72   Max: -11.42
Current: -6302.12

-17680.72
-11.42
Net-margin (%) -6312.99
FOLD's Net-margin (%) is ranked lower than
90% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. FOLD: -6312.99 )
FOLD' s 10-Year Net-margin (%) Range
Min: -16427.82   Max: -10.2
Current: -6312.99

-16427.82
-10.2
ROE (%) -114.69
FOLD's ROE (%) is ranked lower than
85% of the 754 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. FOLD: -114.69 )
FOLD' s 10-Year ROE (%) Range
Min: -319.35   Max: -9.19
Current: -114.69

-319.35
-9.19
ROA (%) -50.94
FOLD's ROA (%) is ranked lower than
71% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -23.16 vs. FOLD: -50.94 )
FOLD' s 10-Year ROA (%) Range
Min: -3515.77   Max: -6.13
Current: -50.94

-3515.77
-6.13
ROC (Joel Greenblatt) (%) -2382.57
FOLD's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: -344.23 vs. FOLD: -2382.57 )
FOLD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2018.52   Max: -157.76
Current: -2382.57

-2018.52
-157.76
Revenue Growth (3Y)(%) -68.20
FOLD's Revenue Growth (3Y)(%) is ranked lower than
89% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. FOLD: -68.20 )
FOLD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -2.6
Current: -68.2

EBITDA Growth (3Y)(%) -12.40
FOLD's EBITDA Growth (3Y)(%) is ranked lower than
61% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. FOLD: -12.40 )
FOLD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 82.8
Current: -12.4

0
82.8
EPS Growth (3Y)(%) -10.10
FOLD's EPS Growth (3Y)(%) is ranked lower than
52% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. FOLD: -10.10 )
FOLD' s 10-Year EPS Growth (3Y)(%) Range
Min: -85.2   Max: 59.5
Current: -10.1

-85.2
59.5
» FOLD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

FOLD Guru Trades in Q2 2014

George Soros 70,500 sh (New)
RS Investment Management Sold Out
Jim Simons Sold Out
Charles Brandes Sold Out
Chuck Royce 283,700 sh (-9.56%)
» More
Q3 2014

FOLD Guru Trades in Q3 2014

RS Investment Management 1,248,215 sh (New)
Steven Cohen 195,900 sh (New)
Jim Simons 130,400 sh (New)
Charles Brandes 36,700 sh (New)
Paul Tudor Jones 78,079 sh (New)
Chuck Royce Sold Out
George Soros Sold Out
» More
Q4 2014

FOLD Guru Trades in Q4 2014

Louis Moore Bacon 225,000 sh (New)
Jim Simons 508,700 sh (+290.11%)
RS Investment Management 2,850,955 sh (+128.40%)
Paul Tudor Jones 98,522 sh (+26.18%)
Charles Brandes Sold Out
Steven Cohen Sold Out
» More
Q1 2015

FOLD Guru Trades in Q1 2015

Steven Cohen 173,900 sh (New)
Jim Simons Sold Out
RS Investment Management 2,564,545 sh (-10.05%)
Louis Moore Bacon 140,641 sh (-37.49%)
Paul Tudor Jones 11,620 sh (-88.21%)
» More
» Details

Insider Trades

Latest Guru Trades with FOLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.00
FOLD's P/B is ranked lower than
117% of the 713 Companies
in the Global Biotechnology industry.

( Industry Median: 3.32 vs. FOLD: 11.00 )
Ranked among companies with meaningful P/B only.
FOLD' s 10-Year P/B Range
Min: 0.87   Max: 14.42
Current: 11

0.87
14.42
P/S 1281.60
FOLD's P/S is ranked lower than
145% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: 7.28 vs. FOLD: 1281.60 )
Ranked among companies with meaningful P/S only.
FOLD' s 10-Year P/S Range
Min: 0.84   Max: 1281.6
Current: 1281.6

0.84
1281.6
Current Ratio 7.19
FOLD's Current Ratio is ranked higher than
64% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. FOLD: 7.19 )
Ranked among companies with meaningful Current Ratio only.
FOLD' s 10-Year Current Ratio Range
Min: 3.46   Max: 18.26
Current: 7.19

3.46
18.26
Quick Ratio 7.19
FOLD's Quick Ratio is ranked higher than
65% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. FOLD: 7.19 )
Ranked among companies with meaningful Quick Ratio only.
FOLD' s 10-Year Quick Ratio Range
Min: 3.46   Max: 18.26
Current: 7.19

3.46
18.26

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.30
FOLD's Price/Net Cash is ranked lower than
116% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. FOLD: 19.30 )
Ranked among companies with meaningful Price/Net Cash only.
FOLD' s 10-Year Price/Net Cash Range
Min: 1.06   Max: 148.75
Current: 19.3

1.06
148.75
Price/Net Current Asset Value 19.30
FOLD's Price/Net Current Asset Value is ranked lower than
114% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. FOLD: 19.30 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
FOLD' s 10-Year Price/Net Current Asset Value Range
Min: 1.02   Max: 99.17
Current: 19.3

1.02
99.17
Price/Tangible Book 16.60
FOLD's Price/Tangible Book is ranked lower than
125% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. FOLD: 16.60 )
Ranked among companies with meaningful Price/Tangible Book only.
FOLD' s 10-Year Price/Tangible Book Range
Min: 0.96   Max: 54.09
Current: 16.6

0.96
54.09
Price/Median PS Value 99.70
FOLD's Price/Median PS Value is ranked lower than
144% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. FOLD: 99.70 )
Ranked among companies with meaningful Price/Median PS Value only.
FOLD' s 10-Year Price/Median PS Value Range
Min: 0.07   Max: 90.67
Current: 99.7

0.07
90.67
Earnings Yield (Greenblatt) -7.90
FOLD's Earnings Yield (Greenblatt) is ranked lower than
66% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. FOLD: -7.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
FOLD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -8   Max: 3784.9
Current: -7.9

-8
3784.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AM6.Germany,
Amicus Therapeutics Inc incorporated under the laws of the State of Delaware on February 4, 2002. The Company is a Biopharmaceutical Company focused on the discovery, development and commercialization of next-generation medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (LSDs). IT is focused on developing pharmacological chaperones as monotherapy agents (to be used without ERT) and its Chaperone-Advanced Replacement Therapy, or CHART platform of pharmacological chaperones in combination with ERT. Chaperone-Advanced Replacement Therapy, or CHART, platform has been used to develop our next-generation ERTs by co-formulating therapeutic enzymes with our proprietary pharmacological chaperones. It is also developing migalastat HCl as a monotherapy in two Phase 3 global registration studies ("Study 011" and "Study 012") for Fabry patients with genetic mutations that were amenable to this pharmacological chaperone in a cell-based assay. Study 011 is a 24-month study consisting of a 6-month double-blind, placebo-controlled treatment period (Stage 1); a 6-month open-label follow-up period (Stage 2); and a 12-month open-label extension phase. The Company currently operates in one business segment focusing on the development and commercialization of small molecule, orally administered therapies to treat a range of human genetic diseases. Its major competitors include pharmaceutical and biotechnology companies in the U.S. and abroad that have approved therapies or therapies in development for lysosomal storage disorders within our core programs. The Company owns certain trademarks in the U.S. and/or abroad, including A AMICUS THERAPEUTICS & design, AMICUS THERAPEUTICS and CHART.
» More Articles for FOLD

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Globus Medical Inc, Diplomat Pharmacy Inc, Zendesk Inc, and Amicus Thera Mar 28 2015 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 09 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 07 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 04 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 08 2009 
iwillbeback note on FOLD Sep 03 2008 

More From Other Websites
Amicus Therapeutics' Fabry Monotherapy Granted Accelerated Assessment by European Regulators May 26 2015
Amicus Therapeutics' Fabry Monotherapy Granted Accelerated Assessment by European Regulators May 26 2015
7:00 am Amicus Therapeutics confirms that the EMA CHMP has granted Accelerated Assessment for the... May 26 2015
AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 19 2015
10-Q for Amicus Therapeutics, Inc. May 07 2015
Amicus Therapeutics Announces First Quarter 2015 Financial Results and Corporate Updates May 05 2015
Amicus Therapeutics reports 1Q loss May 05 2015
Amicus Therapeutics reports 1Q loss May 05 2015
AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 05 2015
Amicus Therapeutics Announces First Quarter 2015 Financial Results and Corporate Updates May 05 2015
Zacks Rank #1 Additions for Tuesday - Tale of the Tape May 05 2015
Q1 2015 Amicus Therapeutics Inc Earnings Release - After Market Close May 05 2015
Amicus Therapeutics to Announce First Quarter 2015 Financial Results on May 5, 2015 May 01 2015
Amicus Therapeutics to Announce First Quarter 2015 Financial Results on May 5, 2015 May 01 2015
AMICUS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Apr 28 2015
Tuesday Morning Corporation (TUES), Swift Transportation Co (SWFT), Amicus Therapeutics, Inc.... Apr 28 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International Apr 27 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International Apr 27 2015
AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 13 2015
Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day Apr 09 2015
Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day Apr 09 2015
Amicus Therapeutics Slumps: FOLD Falls 6.8% in Session - Tale of the Tape Mar 23 2015
Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog Mar 20 2015
Stocks sold off on Thursday — except for the one sector people are calling a bubble Mar 19 2015
Amicus to seek Fabry disease drug approval Mar 19 2015
Amicus to seek Fabry disease drug approval Mar 19 2015
Amicus Therapeutics (FOLD) Stock Spikes Today Following Accelerated Approval Filing Plan Mar 19 2015
Amicus Up As FDA, EU Green-light Quick Drug Filings Mar 19 2015
Amicus Therapeutics shares rally on news of positive regulatory meetings Mar 19 2015
Amicus Therapeutics Provides Positive Global Regulatory Updates From EMA and FDA Meetings for Fabry... Mar 19 2015
Amicus Therapeutics reports 4Q loss Mar 03 2015
Amicus Therapeutics Announces Full-Year 2014 Financial Results and Corporate Updates Mar 03 2015
Amicus Therapeutics to Present at Cowen and Company 35th Annual Health Care Conference Feb 26 2015
Amicus Therapeutics to Announce Full-Year 2014 Financial Results on March 3, 2015 Feb 25 2015
Amicus Therapeutics Provides Full-Year 2015 Strategic Outlook and Financial Guidance Jan 12 2015
Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac Endpoints From Fabry Monotherapy... Jan 08 2015
Amicus Therapeutics Added to NASDAQ Biotechnology Index (NBI) Dec 22 2014
Amicus Therapeutics to Present Program Updates at 33rd Annual J.P. Morgan Healthcare Conference Dec 22 2014
Amicus Therapeutics to Submit European Marketing Application for Migalastat Monotherapy for Fabry... Dec 11 2014
Amicus Therapeutics to Present at Oppenheimer Healthcare Conference Dec 04 2014
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of... Nov 24 2014
Amicus Therapeutics Prices Underwritten Offering of Common Stock Nov 21 2014
Amicus Therapeutics Announces Public Offering of Common Stock Nov 17 2014
Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry... Nov 15 2014
Amicus Therapeutics posts 3Q loss Nov 06 2014
Amicus Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Updates Nov 06 2014
US STOCKS-Wall St set to dip after retailer results; Fed minutes due Aug 20 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK